Clifford Chance advises Gilde Healthcare on financing the combined acquisition of Artinis and NIRx

18 July 2025

Boudewijn Vermeer, Jeroen Kolthof, Stern Flik, Robin Houtveen, Simon Reitz, André Michael Weber, Christian Cranmore, Peter Gierl, Paul Koppel, Ivona Dimov, Avrohom Gelber, Gil Shauly, Jason C. Ewart, Rebecca Isaacs, Ishrath Ahmed
Amsterdam, Frankfurt, Munich, New York

Clifford Chance advises Gilde Healthcare on financing the combined acquisition of Artinis and NIRx

Global law firm Clifford Chance has advised specialised healthcare investor Gilde Healthcare on financing the combined private equity investments in Artinis Medical Systems (Netherlands) and NIRx Medical Technologies (Germany/United States), both pioneers in functional Near-Infrared Spectroscopy (fNIRS) solutions, a differentiated neuroimaging technology. This dual transaction brings together two highly complementary companies, establishing a new global leader in fNIRS.

The investment via two parallel transactions was executed in a proprietary setting, leveraging Gilde’s own developed investment thesis, broad network and deep expertise in the research tools sector. Read more about the transaction here.

The cross-border Clifford Chance team was led by Boudewijn Vermeer and further consisted of Jeroen Kolthof, Emma Trooster (all Global Financial Markets), Stern Flik and Robin Houtveen (both Tax), in Amsterdam, Simon Reitz and André Weber (both Global Financial Markets) in Frankfurt, Christian Cranmore and Peter Gierl (both Global Financial Markets) in Munich, and Paul Koppel, Ivona Dimov (both ERISA), Avrohom Gelber, Gil Shauly (both Tax), Jason Ewart, Rebecca Isaacs and Ishrath Ahmed (all Global Financial Markets) in New York.